Xuan Wu

Dr. Xuan Wu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2024 in Biotechnology Letters
Verified
Journal Article
Closed access
PDF file
NPNingning Pi
Ningning Pi
RXRong Xiang
Rong Xiang
LZLu Zhu
Lu Zhu
YLYi Li
Yi Li
XWXuan Wu
Xuan Wu

23 September 2022 in Viruses
Verified
Journal Article
Open access
PDF file
CLCui-Cui Liu
Cui-Cui Liu
DLDe-Jian Liu
De-Jian Liu
XYXin-Yu Yue
Xin-Yu Yue
XZXiuqin Zhong
Xiuqin Zhong
XWXuan Wu
Xuan Wu
Lei DengLei Deng
Lei Deng
Influenza virus hemagglutinin (HA) stem is currently regarded as an extremely promising immunogen for designing universal influenza vaccines. The appropriate antigen-presenting vaccine vector would be conducive to increasing the immunogenicity of the HA stem antigen. In this study, we generated chimeric virus-like particles (cVLPs) co-displaying the truncated C-terminal of DnaK from Escherichia coli and H1 stem or full-length H1 antigen using the baculovirus expression system. Transmission electronic micrography revealed the expression and presentation of H1 stem antigens on the surface of VLPs. Vaccinations of mice with the H1 stem cVLPs induced H1-specific immune responses and provided heterologous immune protection in vivo, which was more effective than vaccinations with VLPs displaying H1 stem alone in protecting mice against weight loss as well as increasing survival rates after lethal influenza viral challenge. The results indicate that the incorporation of the truncated C-terminal of DnaK as an adjuvant protein into the cVLPs significantly enhances the H1-specific immunity and immune protection. We have explicitly identified the VLP platform as an effective way of expressing HA stem antigen and revealed that chimeric VLP is an vaccine vector for developing HA stem-based universal influenza vaccines.

8 July 2025 in Microbial Biotechnology
Verified
Journal Article
Open access
XWXuan Wu
Xuan Wu
XHXinjing Han
Xinjing Han
LZLu Zhu
Lu Zhu
NPNingning Pi
Ningning Pi
YLYi Li
Yi Li
RXRong Xiang
Rong Xiang
Carbapenem resistance driven by metallo‐β‐lactamases (MBLs) poses a formidable global challenge as these enzymes can degrade a wide range of β‐lactam antibiotics, including last‐line carbapenems. Despite extensive documentation of MBL‐producing pathogens, their evolutionary origins and ecological reservoirs are still poorly understood. Here, we report the discovery and in‐depth characterisation of AMM‐1, a previously unrecognised B1.2 MBL identified within a metagenome‐assembled genome of Alteromonas mangrovi obtained from the Yangtze River Estuary. Comparative sequence analyses and phylogenetics reveal that AMM‐1 clusters closely with clinically significant MBLs, underscoring its potential impact to human health. Structural modelling confirms the presence of a conserved di‐zinc binding site critical for β‐lactam hydrolysis, while heterologous expression in Escherichia coli ( E. coli ) demonstrates a marked increase in resistance against multiple β‐lactam classes, including carbapenems. Phylogenetic depth analysis and ancestral reconstruction delineate AMM‐1's distinct evolutionary path, placing it deeper than IMP‐1 and SPM‐1 but shallower than NDM‐1. Flexibility simulations reveal unique active‐site loop dynamics (L3 and L10), with reduced mobility in key regions that shape substrate binding stability and spectrum. Notably, AMM‐1 is stably located on the host chromosome without flanking mobile genetic elements, suggesting that it may have persisted as a vertically inherited trait rather than a recently acquired component of a mobile resistome. These findings highlight the capacity of environmental microbes to serve as long‐standing, cryptic reservoirs of potent resistance determinants, emphasising the need for integrated environmental surveillance and preemptive stewardship strategies. By unveiling the molecular and functional properties of AMM‐1, this work provides critical insights into how resistance elements can reside, evolve and potentially mobilise within natural habitats, ultimately informing efforts to predict and mitigate the future emergence of carbapenem‐resistant bacterial pathogens.

16 July 2026 in iScience
Verified
Journal Article
Open access
NPNingning Pi
Ningning Pi
XHXiaoyao He
Xiaoyao He
LZLu Zhu
Lu Zhu
XHXinjue Hou
Xinjue Hou
XWXiaoyan Wu
Xiaoyan Wu
XWXuan Wu
Xuan Wu

5 June 2026 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
NPNingning Pi
Ningning Pi
XHXiaoyao He
Xiaoyao He
JZJuan Zhang
Juan Zhang
LZLu Zhu
Lu Zhu
XWXiaoyan Wu
Xiaoyan Wu
XWXuan Wu
Xuan Wu
Environmental detection of antimicrobial resistance has expanded rapidly, but many programs still treat detection of antibiotic resistance genes (ARGs) or resistant bacteria as the primary endpoint. As a result, outputs are often only weakly linked to antibiotic exposure conditions and remain difficult to compare, interpret, and use consistently for follow-up decisions. This review examines how detection of antibiotics and ARG/ARB can be standardized for regulatory interpretation and qualitative concern tiering. It defines standardization across pre-analytical, analytical, data, and interpretive layers; proposes a minimum detection package; and describes how comparison-ready chemical and biological outputs can support integrated interpretation. It also reviews chromatographic, sequencing, biosensor, and other recognition-based platforms, arguing that platform choice should match screening, confirmation, quantification, or discovery roles. This review then outlines a four-tier framework for concern and decision priority, together with reporting and implementation elements needed to translate detection results into proportionate follow-up. Environmental AMR detection becomes more useful when antibiotic exposure, ARG/ARB evidence, and contextual information are standardized and interpreted together rather than handled as separate streams.